PCA
SAGE

Pallas Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Pallas Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,095
Closed -$147K – 943
2025
Q2 		$147K Sell
16,095
-4,814
-23% -$35.4K 0.01% 779
2025
Q1 		$166K Buy
+20,909
New +$153K 0.01% 695

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pallas Capital Advisors's SAGE Position: Q3 2025 in Review

Pallas Capital Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 16,095 shares — an estimated $147K sold.

Pallas Capital Advisors first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $166K in Q1 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Pallas Capital Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 16,095 Sage Therapeutics shares in Q3 2025, an estimated $147K.
  • Pallas Capital Advisors first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
  • Pallas Capital Advisors's Sage Therapeutics position peaked at $166K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Pallas Capital Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.